Lantheus Holdings (LNTH) Change in Receivables (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Change in Receivables of $2.2 million for Q1 2026, down 91.53% year-over-year from $26.4 million in Q1 2025, and up 7.98% quarter-over-quarter from $2.1 million in Q4 2025.
Lantheus Holdings (LNTH) Change in Receivables (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Change in Receivables for 13 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 91.53% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at -$6.2 million (down 172.53% YoY), while the FY2025 annual figure was $17.9 million, down 52.53% from the prior year.
- Change in Receivables improved to $2.2 million in Q1 2026 per LNTH's latest filing, from $2.1 million in the prior quarter.
- Across five years, Change in Receivables topped out at $85.2 million in Q1 2022 and bottomed at -$43.1 million in Q3 2024.
- Historically, Change in Receivables has averaged $15.0 million across 5 years, with a median of $14.4 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 3529.8% — and 2024, when it tumbled 1187.77%.
- Lantheus Holdings' Change in Receivables stood at $16.4 million in 2022, then soared by 55.78% to $25.6 million in 2023, then slumped by 128.14% to -$7.2 million in 2024, then surged by 128.7% to $2.1 million in 2025, then gained by 7.98% to $2.2 million in 2026.
- Business Quant data shows LNTH's Change in Receivables at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | -3.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.28 Mn |
| Jun 30, 2026 | -3.28 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 26.36 Mn |
| Mar 31, 2025 | 26.36 Mn |
| Dec 31, 2024 | -7.20 Mn |
| Dec 31, 2024 | -7.20 Mn |
| Sep 30, 2024 | -43.14 Mn |
| Sep 30, 2024 | -43.14 Mn |
| Jun 30, 2024 | 32.59 Mn |
| Jun 30, 2024 | 32.59 Mn |
| Mar 31, 2024 | 55.44 Mn |
| Mar 31, 2024 | 55.44 Mn |